Samumed
SM04554, a Wnt activator from Samumed, is currently the only new drug worldwide at a phase 3 trial for androgenic alopecia. Last month, Samumed’s CEO Osman Kibar was featured in a Fierce Biotech article which covered Samumed’s various programs for oncology, arthritis, and of course – alopecia. At the end of the article there was…
Read More
Updated 2/28/20 Samumed SM04554 Phase 3 Trial Is Now Fully Enrolled In a company newsletter published on February 28, 2020, Samumed announced that their phase 3 trial of SM04454 in AGA has finally reached its quota of trial participants. That quota was a whopping 625 male subjects between the ages of 18 – 45 years…
Read More
It looks like we may have another approved treatment on the market within the next 2 years. Today, Samumed released a newsletter addressing its program for androgenic alopecia, and stated that the company “has conducted an Investigator Meeting to initiate our upcoming 625-patient Phase 3 clinical trial.” While the results from the phase 2 trial…
Read More
Hello Everyone, It is good to be back for another Weekly Thoughts. This edition is headlined by an anti-aging technology from The Netherlands that has shown interesting regenerative effects on mice. I even got some exclusive info on the potential of this technology to be applied to hair growth to share with you. Also, we…
Read MoreHey there everybody, nice to see you all again. In this edition of Weekly Thoughts we find a new company with some ambiguous, yet noteworthy, claims about their hair growth technology, an update on Follica’s new pivot, and some background information on Samumed’s founder and CEO. Thorn Medical Makes Big Claim Last week, a press…
Read MoreWhat is most significant and encouraging about this new data is the SM04554 treatment was applied for only 90 days, but continued to have positive results all the way until 135 days. The chart shows that during the 45 days after the treatment was stopped, there was still a continual increase in hair count from…
Read MoreHello Everybody, As always, it is nice to be here with you to report on the latest hair growth related news for this edition of Weekly Thoughts. Major Gene Study All About Follicles A study lead by Kaustubh Adhikari of University College London has mapped out a gene analysis for some of the major characteristics…
Read MoreAn important bit of news surfaced online this weekend about the company Samumed and their heralded phase 2 results. Samumed will be presenting “Safety, Tolerability and Efficacy of a Topical Treatment (SM04554) for Androgenetic Alopecia (AGA): Results from a Phase 2 Trial” on March 5th, 2016 at the 74th Annual Meeting of the American Academy…
Read MoreHere we are in a new year which is always a good thing for technological advancements. I’m going to get right into things here with a look at the hair technology happenings I am most looking forward to in 2016: 1. Samumed’s Phase II efficacy results. Samumed has probably had the smoothest development progress of…
Read MoreThe Holiday season is in full swing, and there is a lot to be happy about in the world of hair regeneration. For starters, Histogen and Replicel should both be available within about two years time. See previous post for expanded info. Also in this issue, I’m really excited about the new patents Angela Christiano…
Read More